[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.232.99. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1984

Flurbiprofen Pretreatment in Argon Laser Trabeculoplasty for Primary Open-Angle Glaucoma

Author Affiliations

From the Departments of Ophthalmology, the University of California, San Diego (Dr Weinreb); The Johns Hopkins University, Baltimore (Dr Robin); the University of Southern California, Los Angeles (Dr Baerveldt); the University of California, San Francisco (Dr Drake); the Chaim Sheba Medical Center, Tel Hashomer, Israel (Dr Blumenthal); and the University of Illinois, Chicago (Dr Wilensky).

Arch Ophthalmol. 1984;102(11):1629-1632. doi:10.1001/archopht.1984.01040031319016
Abstract

• We examined the influence of topically administered flurbiprofen sodium 0.03%, a potent prostaglandin inhibitor, on the inflammatory response and intraocular pressure following argon laser trabeculoplasty. Our investigation included one eye of each of 118 patients with primary open-angle glaucoma in whom laser trabeculoplasty was indicated. Sixty-three patients received flurbiprofen and 55 received a vehicle during the two-hour period immediately preceding laser therapy and for one week postoperatively. No significant differences in postoperative IOPs were noted between groups. However, when we considered conjunctival erythema at 24 hours or control of inflammation at the termination of the investigation, the eyes receiving flurbiprofen had less inflammation than did the vehicle-treated eyes.

×